AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Ulcer Prevention II
Phase 3
Completed
- Conditions
- NSAID Associated Gastric Ulcers
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 800
- Registration Number
- NCT00629928
Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EU
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2012-10-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 613
- Registration Number
- NCT00628862
- Locations
- 🇺🇦
Research Site, Kyiv, Ukraine
Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2019-12-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 97
- Registration Number
- NCT00628251
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: beta-II-agonist, inhale steroid
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2012-08-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 430
- Registration Number
- NCT00628758
- Locations
- 🇹🇷
Research Site, Zonguldak, Turkey
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD)
Phase 4
Completed
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 600
- Registration Number
- NCT00628342
Chronic Posterior Laryngitis With Suspected Laryngopharyngeal Reflux
Phase 4
Completed
- Conditions
- Chronic Posterior Laryngitis (CPL)
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT00628667
Tolerability/Safety and Efficacy of Inhaled AZD4818 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2010-12-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 65
- Registration Number
- NCT00629239
- Locations
- 🇸🇪
Research Site, Lund, Sweden
Adult Asthmatics and Acid Reflux
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2009-03-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1400
- Registration Number
- NCT00628953
Aclidinium/Formoterol Fixed Combination Dose Finding Study
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2016-11-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 808
- Registration Number
- NCT00626522
- Locations
- 🇷🇺
Research Site, Yaroslavl, Russian Federation
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2012-09-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2577
- Registration Number
- NCT00626548
- Locations
- 🇬🇧
Research Site, Newcastle upon Tyne, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath